linjc16/ctgov huggingface dataset:
Tennis Elbow Patients Undergoing Closed Therapy Can Easily Cause Tendon Tear

Study Overview
=================
Brief Summary
-----------------
To explore whether there is a difference in the rate of tendon tear after hyperlipemia in tennis elbow patients and those with normal blood lipids after closed treatment, which provides clues for further exploration of its mechanism. 1. Collect data from 108 cases of tennis elbow patients treated at the Institute of Sports Medicine, Peking University Third Hospital from January 2010 to December 2018 at the Institute of Sports Medicine, Peking University Third Hospital. Statistics included the sex, age, BMI, number of closures, total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein. 2. Retrieve the MRI imaging data of the above-mentioned patients, and use the extensor tendon at the humerus to see if there is a tear as an observation indicator. Analyze the difference of tendon tear after closed treatment in patients with high blood fat and normal blood fat.

Official Title
-----------------
Tennis Elbow Patients Undergoing Closed Therapy Can Easily Cause Tendon Tear

Conditions
-----------------
MRI, Tennis Elbow, Hyperlipidemia

Intervention / Treatment
-----------------
* Other: classification statistics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with tennis elbows in our hospital Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: classification statistics|Without any intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Use MRI to assess whether the tendon is torn | One sports medicine surgeon and one musculoskeletal radiologists, being blinded to the patients' information, reviewed the elbow MRI independently. The common extensor tendon (CET) abnormalities were evaluated on axial and coronal fat-suppressed T2-weighted FSE image. Tendinosis group was defined as an increased signal intensity, but lower than the fluid signal on T2-weighted images and/ or an increased tendon thickness. Tendon tear group contain a partial thickness tear defined as a region with fluid-signal-intensity that extended partway across the tendon and a full thickness tear appeared as a gap of fluid-signal-intensity across the entire tendon substance. | 3 months |
Codesign of an Optical Device to Measure Urine Flow and Volume

Study Overview
=================
Brief Summary
-----------------
The study is seeking to understand the needs of patients and healthcare practitioners for an innovation in the way that changes in bladder function are assessed. This information will be used in the design and evaluation of a device, being developed in parallel, that assesses changes to the volume and flow of urine in order to determine changes in bladder function. In order to ensure development is optimal, the principal research objective is therefore to understand the needs of patients and healthcare practitioners (ranging from care home staff and GPs in primary care, to urologists in tertiary referral centres).

Official Title
-----------------
Conducting Focus Groups With Patients and Healthcare Practitioners to Inform the Development of a Sensor Which Measures Urine Flow, Volume and Voiding Patterns, in Order to Diagnose Pathologies of the Urinary System

Conditions
-----------------
Urinary Incontinence, Urinary Retention, Urinary Tract Infections, Overactive Bladder, Benign Prostatic Hyperplasia, Underactive Bladder

Intervention / Treatment
-----------------
* Other: Focus Group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria The participant is willing and able to give informed consent for participation in the study. Aged 18 years or above. Male or Female. Exclusion criteria The participant is unwilling or unable to give informed consent for participation in the study. Aged 17 years or younger.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Focus Group|Focus Groups to capture information about the need for innovation in the diagnosis and monitoring of urinary symptoms.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Understanding the needs of patients and healthcare practitioners for an innovation in the way that changes in bladder function are assessed. | For  45 participants for each of two categories, patients and healthcare practitioners, focus groups will chart the difficulties, needs, potential solutions, and concerns of all participants, as well as collect their input on the prototype that we are developing. Their responses will be coded, grouped, and summarised, to create a set of guidelines aiding the future development of solutions for urinary disorders. | November 2022 - February 2023 |
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Study Overview
=================
Brief Summary
-----------------
This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.

Official Title
-----------------
International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting

Conditions
-----------------
Transfusional Hemosiderosis

Intervention / Treatment
-----------------
* Drug: deferasirox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Patients treated with deferasirox for transfusional hemosiderosis according to the local prescribing information. (the patients are either beginning treatment with deferasirox at the time of enrollment in the sentinel site monitoring or are currently under treatment with deferasirox and have started the treatment under prescription up to twelve months prior to enrollment in the sentinal site monitoring. Exclusion Criteria: Patients with non-transfusional hemosiderosis Patients treated with deferasirox in an interventional clinical trial Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| deferasirox<br> | Drug: deferasirox<br> <br> * Other names: ICL670;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum Creatinine and liver enzyme levels | Observed over 3 years for each patient | 3 years | 
| Adverse Drug Reactions | Observed over 3 years for each patient | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
iron overload, iron chelation, deferasirox, observational
Greek Physicians Perceptions Regarding Generics Prescribing in Glaucoma

Study Overview
=================
Brief Summary
-----------------
This attempts to investigate the perceptions of Greek Ophthalmologists regarding generics prescription in glaucoma by means of a structured questionnaire.

Detailed Description
-----------------
The following dimensions will be recorded Overall physician's empathy regarding generics in glaucoma Physician's prescribing habits regarding generics in glaucoma Physician's perceptions regarding generics cost-effectiveness in glaucoma Physician's perceptions regarding adequacy of Greek regulatory authorities (generic market in glaucoma) Physician's perceptions regarding adequacy of European regulatory authorities (generic market in glaucoma)

Official Title
-----------------
Greek Physicians Perceptions Regarding Generics Prescribing in Glaucoma

Conditions
-----------------
Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Licensed Registration to Greek Ophthalmology Council Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Generic Perception |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Greece, Ophthalmology, Glaucoma, Generics, Perception
Cardiovascular Consequences After COVID-19

Study Overview
=================
Brief Summary
-----------------
The occurrence of cardiovascular complications in SARS-CoV-2 infections appears to be more frequent than in other viral respiratory infections, probably due to a singular pathophysiology of this coronavirus. The lack of characterization of cardiovascular damages linked to Covid-19 could have medium and long-term consequences on the prognosis of patients. This problematic could lead to a second major public health problem linked to Covid-19 and it is therefore crucial to keep monitoring and screening patients at risk. In this context of emerging infectious diseases, of poorly characterized cardiovascular damages during infection and of absence of data on the long-term evolution of the infection, the investigators propose to carry out a prospective and observational cohort study focused on the evaluation and the systematic cardiovascular follow up of patients who survived an episode of Covid-19, regardless of their cardiovascular profiles.

Official Title
-----------------
The CardioPostCovid Study: Cardiovascular Consequences After COVID-19

Conditions
-----------------
Cardiovascular Consequences After an Episode of COVID 19

Intervention / Treatment
-----------------
* Other: Infectious Disease and Cardiology Clinical Consultations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • All adults affiliated to social security attending the post-Covid follow-up consultation, having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered. Exclusion Criteria: Age <18 years old Major under guardianship or curatorship Absence of non-opposition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Covid 19 Patients<br>patients having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered. | Other: Infectious Disease and Cardiology Clinical Consultations<br>* Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of at least one clinical, biological and/or imaging cardiovascular anomaly within 1 month of recovering | Describe clinical, biological and imaging cardiovascular data 1 month after recovery from an episode of Covid-19 | 1 month |
Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy

Study Overview
=================
Brief Summary
-----------------
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC under daily-life treatment conditions.

Official Title
-----------------
Sorafenib Treatment Modalities for HEpatoceLLular Carcinoma Patients in ItAly

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Drug: Sorafenib (Nexavar, BAY43-9006)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histologically/cytologically confirmed HCC or radiographically diagnosed as per AASLD criteria, who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made Patients must have signed the informed consent form Patients must have a life expectancy of at least 8 weeks Inclusion criteria must follow the approved local product information. Exclusion Criteria: Prior treatment with sorafenib Concomitant participation in other clinical studies Exclusion criteria must follow the approved local product information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Sorafenib (Nexavar, BAY43-9006)<br>* Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy (analyzed by overall survival rate) of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma. |  | at 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event collection of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma. |  | every 4 months on average within approx. 2 years | 
| Overall survival |  | at 1 year | 
| Time to Progression |  | every 4 months on average within approx. 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatocellular Carcinoma, Cancer, Liver, Sorafenib, Nexavar
EMEPIC : Value of a Mobile Team of Cardiologist Using Echocardiography for Managing Patients With Acute Heart Failure

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare clinical management of patients with acute decompensation of heart failure, hospitalized in non cardiological ward, with the use of a mobile team including a cardiologist with portable echocardiography and standard care. The hypothesis is that a mobile team will lead to shorter hospitalization.

Detailed Description
-----------------
Randomized, controlled, monocentric study comparing Standard care with the care provided by a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward on the duration of hospitalization, re-hospitalization rate à 30 days, emergency visit within 30 days, treatment at discharge, mortality within hospital stay and at 30 days.

Official Title
-----------------
Value of a Mobile Team of Cardiologist Using Echocardiography for Managing Patients With Acute Heart Failure

Conditions
-----------------
Acute Heart Failure, Congestive Edema, Cardiac Disease

Intervention / Treatment
-----------------
* Procedure: Mobile team
* Procedure: Standard care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized for suspected heart failure > or = 18 years Exclusion Criteria: Refuses to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Mobile Team | Procedure: Mobile team<br>* a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward<br>|
| Active Comparator: 2<br>Standard care | Procedure: Standard care<br>* Standard care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of hospitalization. |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Re-hospitalization rate à 30 days Emergency visit within 30 days Treatment at discharge Mortality within hospital stay Mortality at 30 days |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure, congestive, Echocardiography, Patient care team
Study Evaluating Totelle® in Menopausal Symptoms and Sexual Function

Study Overview
=================
Brief Summary
-----------------
To evaluate the tolerability, bleeding patterns and acceptability of Totelle® 1mg administered to a population of Brazilian women in a continuous combined regime for hormone replacement therapy.

Official Title
-----------------
An Open Assessment of the Effect of Low-Dose Totelle® 1 mg on Menopausal Symptoms, Sexual Function and Quality of Life

Conditions
-----------------
Hot Flashes, Sleep Disorders

Intervention / Treatment
-----------------
* Drug: Totelle®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intact uterus Generally health postmenopausal women 45 to 60 years of age, inclusive Sexually active No hormone replacement therapy within the 90 days immediately prior to the screening evaluation. Exclusion Criteria: Known or suspect estrogen-dependent neoplasia Known hypersensitivity to estrogens, progestins, or other ingredients of Totelle Use of any estrogen, progestin, androgen containing medications or tibolone within 12 weeks before screening.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Totelle®|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the tolerability, bleedeing patterns and acceptability of Totelle 1mg administered to a population of Brazilian women in a continuous combined regime for hormone replacement therapy. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effects of Totelle 1 mg on sexual function and quality of life. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Menopause, Sleep Disorder, Hot Flashes
Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study 1-Survey

Study Overview
=================
Brief Summary
-----------------
Despite widespread and growing popularity of complementary and alternative medicine (CAM) in the US, there currently exist significant gaps in our knowledge regarding CAM use, clinical effectiveness, safety and cost- effectiveness. With previous funding support from NCCAM, the Harvard Medical School (HMS) Osher Research Center established and trained a multidisciplinary integrative team of CAM and conventional providers to work collaboratively to provide state-of-the-art integrative care in a coordinated and individualized fashion. The Osher Integrative Care Center (OCC) was opened in fall 2007, physically located within the Ambulatory Care Center of the Brigham and Women's Hospital (BWH) at 850 Boylston Street in Chestnut Hill, MA. The focus of this survey study is to characterize the decision-making process of both patients and conventional providers with respect to communication about and referral to an integrative care team in an academic hospital outpatient setting.

Official Title
-----------------
Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study 1-Survey

Conditions
-----------------
Medical Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: New patient coming into Osher Clinical Center for any medical reason. Physician affiliated with any of included division/department (see above). Exclusion Criteria: Patient has been seen at Osher Clinical Center within past 3 months for any reason.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| New patients of Osher Clinical Center<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterization of decision-making process for patients of CAM therapies and conventional providers | Surveys will be sent to: 1) 1500 consecutive new patients seen at the OCC over 3.5 years, to characterize the chief complaints; their medical history; referral sources; communication with their physicians; barriers to use of CAM; views regarding and previous use of CAM; and expectations for CAM therapy as adjuncts to their conventional care; 2) 300 BWH physicians from five divisions (Women's Health, Orthopedics, Obstetrics and Gynecology, General Medicine, and Rheumatology) most likely to refer to the OCC, to assess their use of, feelings about, and knowledge of CAM. | 3.5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
integrative medicine, barriers to utilization, communication